Novo Nordisk Announces Positive Phase 2 Trial Results, Shares Spike Higher

Shares of Novo Nordisk A/S NVO were trading higher by more than four percent Friday morning after the company announced positive results from a phase 2 FDA trial. Novo Nordisk announced that it "has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks."